EP4739293A2 - Compositions et méthodes pour le traitement de troubles auto-immuns - Google Patents

Compositions et méthodes pour le traitement de troubles auto-immuns

Info

Publication number
EP4739293A2
EP4739293A2 EP24838953.8A EP24838953A EP4739293A2 EP 4739293 A2 EP4739293 A2 EP 4739293A2 EP 24838953 A EP24838953 A EP 24838953A EP 4739293 A2 EP4739293 A2 EP 4739293A2
Authority
EP
European Patent Office
Prior art keywords
individual
pharmaceutical composition
sjs
keratolytic agent
eyelid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24838953.8A
Other languages
German (de)
English (en)
Inventor
Omer Rafaeli
Yair Alster
Charles Bosworth
Marc GLEESON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azura Ophthalmics Ltd
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of EP4739293A2 publication Critical patent/EP4739293A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour le traitement d'une maladie ou d'un trouble inflammatoire ou auto-immun associé à des états dans ou autour d'un oeil d'un individu en ayant besoin. Lesdites compositions et méthodes comprennent la fourniture d'une composition pharmaceutiquement (par exemple, ophtalmiquement acceptable) comprenant un agent kératolytique à une surface oculaire ou périoculaire de l'individu en ayant besoin.
EP24838953.8A 2023-07-07 2024-07-05 Compositions et méthodes pour le traitement de troubles auto-immuns Pending EP4739293A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363525548P 2023-07-07 2023-07-07
PCT/IB2024/000365 WO2025012700A2 (fr) 2023-07-07 2024-07-05 Compositions et méthodes pour le traitement de troubles auto-immuns

Publications (1)

Publication Number Publication Date
EP4739293A2 true EP4739293A2 (fr) 2026-05-13

Family

ID=94216245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24838953.8A Pending EP4739293A2 (fr) 2023-07-07 2024-07-05 Compositions et méthodes pour le traitement de troubles auto-immuns

Country Status (2)

Country Link
EP (1) EP4739293A2 (fr)
WO (1) WO2025012700A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020259997B2 (en) * 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
US20240158375A1 (en) * 2020-10-21 2024-05-16 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
TW202327641A (zh) * 2021-09-14 2023-07-16 美商三葉草治療有限公司 使用經修飾之fgf-1多肽之治療方法

Also Published As

Publication number Publication date
WO2025012700A2 (fr) 2025-01-16
WO2025012700A3 (fr) 2025-02-13

Similar Documents

Publication Publication Date Title
US12427158B2 (en) Compositions and methods for the treatment of meibomian gland dysfunction
JP7723603B2 (ja) コンタクトレンズ不快感を処置するための組成物および方法
US11911380B2 (en) Compositions and use of varenicline for treating dry eye
WO2025012700A2 (fr) Compositions et méthodes pour le traitement de troubles auto-immuns
US20240285679A1 (en) Compositions and methods for vision improvement
WO2025012701A2 (fr) Administration de kératolytiques à des surfaces oculaires et périoculaires
TW202426011A (zh) 用於視力改善之組合物及方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR